Fosun Pharma (600196.SH; 02196.HK) announced its financial results for the first three quarters of 2026. During this period, the Company recorded operating revenue of RMB30.463 billion, representing a year-on-year increase of 3.64%, or 5.81% at constant exchange rates.
Driven by continued growth in Innovative Drugs revenue and steady improvements in operational efficiency, Fosun Pharma further optimized its revenue and profit mix. In the first three quarters of 2026, the Company achieved a net profit attributable to shareholders of the listed company of RMB2.667 billion, up 5.71% year-on-year; and net profit attributable to shareholders of the listed company after deducting extraordinary gain or loss of RMB1.706 billion, up 8.42% year-on-year.
In the first three quarters of 2026, the Company’s total R&D expenditure reached RMB5.247 billion, a year-on-year increase of 31.24%, while R&D expenses amounting to RMB3.118 billion, up 14.21% year-on-year. Among this, R&D expenditure related to Innovative Drugs reached RMB4.346 billion, an increase of 55.07% year-on-year. In terms of pipeline development, several key products have entered or are successively initiating global multi-center Phase 3 clinical trials. The Company also successfully in-licensed near-commercialization innovative pipelines, including GR1803 and JS005. These initiatives have further enriched and optimized the Company’s core pipeline portfolio, strengthening the commercialization certainty of subsequent products.
Accelerating the Realization of Innovative Achievements
Fosun Pharma continues to focus on three core therapeutic areas: oncology, immunology and inflammation, and neurodegenerative diseases, with innovative-driven achievements translating into tangible progress. In the first three quarters of 2026, a total of 22 indications across 8 Innovative Drugs were approved for marketing. In solid tumors including lung cancer, breast cancer and gastrointestinal tumors, the Company has established differentiated competitive advantages through multi-product synergy and global commercialization.
In oncology, H-drug Han Si Zhuang® (serplulimab injection) received approval in China for the perioperative treatment of gastric cancer, filling a global unmet clinical need. In the European Union, it also received three additional first-line approvals: squamous non-small-cell lung cancer, esophageal squamous-cell carcinoma, and non-squamous non-small-cell lung cancer. Han Bei You® (pertuzumab) received successive marketing approvals in the European Union and China, forming an innovative product portfolio for breast cancer treatment alongside Han Qu You®, Han Nai Jia® and Fu Tuo Ning®. The new drug application (NDA) for the 120 mg (1.7 mL)/vial presentation of the denosumab biosimilar HLX14 (recombinant fully human anti-RANKL monoclonal antibody injection) was accepted by the National Medical Products Administration (NMPA), with proposed indications including bone metastases from solid tumors, multiple myeloma, and giant cell tumor of bone.
Fu Mai Ning® (luvometinib tablets) received approval for a new indication, becoming the world’s first targeted therapy approved for all of the following indications: Langerhans-cell histiocytosis (LCH) in children and adolescents aged 2 years and older; LCH and histiocytic tumors in adults; and neurofibromatosis type 1 (NF1) in children aged 2 years and older and adults.
Meanwhile, Fosun Pharma further expanded its hematologic malignancies pipeline.Weiketuo® (velinotaming injection), anin-licensed product, received conditional approval from NMPA, becoming the first domestically developed original BCMA×CD3 bispecific antibody and providing a new treatment option for adult patients with relapsed or refractory multiple myeloma (RRMM).
In neurodegenerative diseases, the international multi-center Phase3clinical trial (POLARIS-AD) for AR1001, an innovative drug for Alzheimer’s disease that the Company licensed in regionally and holds an exclusive option in core global markets, completed the last patient’s last visit in July 2026. Topline data is expected to be announced in an oral presentation on November 16, 2026 (U.S. Eastern Time), the opening day of the 19th Clinical Trials on Alzheimer’s Disease (CTAD) conference.
Strengthening Innovation Resource Integration and Global Value Realization Capabilities
Leveraging its internationalization strengths, Fosun Pharma continues to accelerate the global expansion of its biosimilars to drive global value realization. In August 2026, Shanghai Henlius (a subsidiary of the Company) entered into a framework agreement with Sandoz AG, under which both parties may enter into licensing collaborations covering registration, commercialization, development, and manufacturing up to 10 monoclonal antibody and/or antibody-drug conjugate (ADC) biosimilar products in relevant overseas regions. Specific commercial terms have been agreed for the first three collaboration products: HLX05-N, HLX16 and a belimumab biosimilar, and an option has been granted to Sandoz AG for an additional potential collaboration product, HLXTE-HAase1001. The Company’s capability to integrate global innovation resources and transform value continue to strengthen.
Fosun Pharma’s innovative achievements have also gained increasing visibility on the international stage, continuously enhancing its global academic influence. In October 2026, Fosun Pharma presented 19 innovative achievements at the 2026 European Society for Medical Oncology (ESMO) Congress, covering core oncology pipeline products including the anti-PD-1 monoclonal antibody H-drug Han Si Zhuang®, the PD-L1 ADC HLX43, and the innovative small molecule CDK4/6 inhibitor Fu Tuo Ning®. Among them, the ASTRIDE study of Han Si Zhuang was selected for an oral presentation at the congress.
Looking ahead, Fosun Pharma will remain firmly committed to innovation, accelerate the translation of the clinical value of innovative products into commercial value. Through scientific leadership and innovation-driven growth, the Company aims to reward the long-standing trust of shareholders and advance toward high-quality development.